A Phase 1 interventional study of Nuvastatic in Covid19, sponsored by Natureceuticals Sdn Bhd. Status unknown at 1 site in India. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-09-10.
Sponsored by Natureceuticals Sdn Bhd · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 113 studies in COVID-19 with a site in India — 7 open to participants now, 9 under way, 4 of them phase 3. COVID-19 · India.
Among the 113 studies in COVID-19 with a site in India, this one is the 69th largest by planned enrollment of the 75 interventional ones that give a count, is one of 53 that started in 2020, is one of 4 in phase 1, and was the 40th registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →7 of the 113 studies in COVID-19 with a site in India are open now. Recruiting first, the newest first:
Boston University · Sites in India, United States
Ages 18–50 · Women only
AstraZeneca · Sites in India, United States, Argentina and 36 more countries
Ages 18+
KARE Biosciences · Sites in India
Ages 18–99
Aventyn, Inc. · Sites in India, United States, Sweden
Ages 18+ · Healthy volunteers
Tuberculosis Research Centre, India · Sites in India
Ages 1–15
A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
113 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 27 · Phase 3 32 · Phase 4 5
First in 2015; this study’s year is marked. 53 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10 is below the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 272 across the 75 interventional studies, 598 across the 38 observational. Of the 78 that completed or were terminated, 22 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
54 of 113 have an industry lead sponsor. The 10 most frequent:
Natureceuticals Sdn Bhd is the lead sponsor of 7 studies on the registry; 3 are open to participants now.
Natureceuticals Sdn Bhd has 1 study filed under COVID-19 — fewer than ten, so there is no comparison to draw.
1 of the studies in COVID-19 with a site in India that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
Add it to your calendar (.ics) → With an account.
Among the 113 studies in COVID-19 with a site in India, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A two arm open label multi-centered randomized interventional trial is proposed to assess aspects of safety and efficacy of Nuvastatic™ (Serial No: C5OSEW5050ESA) . Two parallel groups of (1:1) ratio comparing Nuvastatic™ versus standard care will be conducted on patients on oxygen saturation (SaO2) of 94% or less while they are breathing ambient air or a ratio of the partial pressure of oxygen (Pao2) to the fraction of inspired oxygen (Fio2) (PaO2:FiO2) at or below 300 mg Hg.
Primary Outcome Measures: time to clinical improvement, defined as the time from randomization to an improvement of two points (from the status at randomization) on a seven-category ordinal scale or live discharge from the hospital, whichever comes first.
Secondary Outcome Measures: Clinical status as assessed with the seven-category ordinal scale on days 7 and 14, mortality at day 28.
This study will propose Nuvastiatic™ as a new lead therapeutic agent for SARS-CoV-2, and new insights for currently ongoing clinical trials to treat SARS-CoV-2 infections. Nuvastatic™ could be used as potential anti-coronavirus therapy that acts on the human immune system or human cells as an immune modulator, and the other on coronavirus itself as an antiviral agent. In terms of the human immune system, the innate immune system response plays an important role in controlling the replication and infection of coronavirus, and interferon gamma, interleukins, Th cells, granulocyte macrophage are expected to enhance the immune response.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
5 patients, dosage: 3000 mg of Nuvastatic™ (C5OSEW5050ESA) each day plus standard of care thrice daily (morning, afternoon and evening (one sachet each) to be taken for 14 days in Covid-19 patients.
Drug: Nuvastatic
5 patients, dosage: 3000 mg of placebo each day plus standard of care thrice daily (morning, afternoon and evening (one sachet each) to be taken for 14 days in Covid-19 patients.
Drug: Nuvastatic
Polymolecular botanical standardized extract Orthosiphon stamineus/Orthosiphon aristatas as an immunomodulator adjuvant therapy
Also known as: C5OSEW5050ESA
To evaluate safety and efficacy Nuvastatic™ (C5OSEW5050ESA)
Time to clinical improvement, defined as the time from randomization to an improvement of two points (from the status at randomization) on a seven-category ordinal scale or live discharge from the hospital, whichever comes first.
Time frame: 14 Days
IL-6 reduction
Improvement of Biomarkers: IL-6 reduction
Time frame: 14 Days
Serum c-reactive protein (CRP)
Improvement of Biomarkers:key inflammatory markers Serum c-reactive protein (CRP)
Time frame: 14 Days
IgG
Improvement of Biomarkers:key inflammatory markers IgG
Time frame: 14 Days
Hb
Improvement of Biomarkers:key inflammatory markers Hb
Time frame: 14 Days
Total leucocyte count
Improvement of Biomarkers:key inflammatory markers Total leucocyte count
Time frame: 14 Days
F2-Isoprostane
Improvement of Biomarkers:key inflammatory markers urinary F2-Isoprostane.
Time frame: 14 Days
Improvement in ARDS associated clinical symptoms cause
Role of VEGF as potential therapeutic target in acute respiratory distress syndrome (ARDS)
Time frame: 14 Days
Plan to share: No — Institutional sharing
No publications or documents are linked to this record.
Started Sep 2020 (actual). Primary completion is estimated for Sep 2020, 0 months after the start.
Of 233 industry-sponsored phase 1 interventional studies under COVID-19, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 12. This study's planned 0 months is below that.
Counting every sponsor, half of 384 studies reached it within 7 months; a quarter within 3 and three quarters within 15.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.